Table 1.
Baseline characteristics of participants in the ISS and OSS groups (n=100)
| ISS group | OSS group | |
|---|---|---|
| Number of participants | 48* | 49† |
| Number of females/males | 42/6 | 43/6 |
| Median age (range) | 44.5 (26–63) | 42 (27–65) |
| Median years of obstetric work experiences (range) | 7 (0.6–38) | 7 (0.6–39) |
| Previous simulation experiences‡ | ||
| No experience | 8 | 10 |
| Simple simulation | 25 | 24 |
| Full-scale simulation | 15 | 15 |
| Pregnant participants | 2 | 2 |
| Participants on any kind of medication | 19 | 20 |
| Participants on medication with no expected influence on cortisol measurement§ | 12 | 9 |
| Participants on medication with potential influence on cortisol measurement | 7 | 11 |
| Intranasal and inhaled corticosteroids (mometasone furoate, budesonide/formoterol, budesonide, fluticasone/salmeterol) | 2 | 3 |
| Levothyroxine | 1 | 2 |
| Metformin | 1 | 1 |
| Norethisterone/estradiol acetate | 0 | 1 |
| Oral contraceptives | 1 | 3 |
| Beta blockers (metoprolol) | 0 | 1 |
| Antidepressants (nortriptyline, fluoxetine) | 2 | 0 |
*Not included due to illness: A consultant obstetrician and an operating room nurse (n=2).
†Not included due to illness: An auxiliary nurse (n=1).
‡A simple simulation experience is, for example, skills training using a low-tech delivery mannequin and no video recording of the simulation scenario. Full-scale simulation is, for example, done in teams with fully interactive mannequins and video recorded scenarios.
§Intrauterine contraceptive devices, angiotensin II receptor antagonists, angiotensin-converting-enzyme inhibitors, simvastatin, alendronate, pantoprazole, antihistamine and tinzaparine.
ISS, in situ simulation; OSS, off-site simulation.